Forte Biosciences, INC Form 4 insider transactions

Steven Kornfeld, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

David W Gryska, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Richard G Vincent, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Barbara K Finck, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Shivpreet Singh Kapoor, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Stephen K Doberstein, a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Antony A Riley, CHIEF FINANCIAL OFFICER of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Paul A. Wagner, SEE REMARKS and a Director of Forte Biosciences, Inc., reported multiple transactions in common stock on August 27, 2026.

Forte Biosciences CFO Antony A. Riley reports transactions involving common stock and restricted stock units, including acquisitions and disposals.

Paul A. Wagner, Director and Officer of Forte Biosciences, Inc., acquired 1,250 Restricted Stock Units (RSUs) on July 1, 2026, as detailed in a Form 4 filing.

Forte Biosciences CFO Antony A. Riley acquired 22,000 stock options with an exercise price of $17.15, vesting over four years starting June 16, 2026.

Forte Biosciences, Inc. reports the grant of stock options to Director and Officer Paul A. Wagner, with vesting over four years.

Forte Biosciences, Inc. director Stephen K. Doberstein was granted 18,353 restricted stock units (RSUs) on May 29, 2026, vesting on the first annual stockholder meeting after that date.

Forte Biosciences, Inc. director Shivpreet Singh Kapoor was granted 18,353 restricted stock units, vesting on the first annual stockholder meeting after May 29, 2026.

Forte Biosciences, Inc. director Richard G. Vincent acquired 18,353 restricted stock units (RSUs) on May 29, 2026, with vesting contingent on continued service.

Forte Biosciences, Inc. director David W. Gryska was granted 18,353 restricted stock units, vesting on the first annual meeting after May 29, 2026.

Forte Biosciences Director Scott C. Brun was granted 18,353 Restricted Stock Units (RSUs) vesting in May 2026.

Forte Biosciences Director Steven Kornfeld reports the grant of 18,353 Restricted Stock Units (RSUs) vesting on the first annual meeting after May 29, 2026.

Forte Biosciences CFO Antony A. Riley acquired 375 shares of common stock through restricted stock units and disposed of 134 shares.

Paul A. Wagner, a Director and Officer of Forte Biosciences, Inc., acquired 1,250 Restricted Stock Units (RSUs) on April 1, 2026.

Forte Biosciences' Chief Financial Officer, Antony A. Riley, was granted 150,000 equity awards, including stock options and restricted stock units, vesting over four years.

Forte Biosciences, Inc. reported an equity grant to CEO, Secretary, and Chair of the Board Paul A. Wagner, including 270,000 stock options and 180,000 restricted stock units.

Forte Biosciences' CEO, Paul A. Wagner, reported the vesting of 1,250 restricted stock units and the subsequent disposition of 164 shares for tax withholding.

Forte Biosciences' Chief Financial Officer, Antony A. Riley, increased his direct ownership through a significant share purchase and RSU vesting, alongside a disposition for tax purposes.

Forte Biosciences' Chief Financial Officer, Antony A. Riley, reported the exercise of restricted stock units and subsequent disposition of shares for tax obligations.

Paul A. Wagner, CEO of Forte Biosciences, exercised restricted stock units and sold a portion of the resulting shares for tax obligations.

Forte Biosciences, Inc.'s Chief Financial Officer, Antony A. Riley, reported the vesting of 375 restricted stock units and the subsequent disposition of 134 shares for tax purposes on July 1, 2025.

Forte Biosciences, Inc. CEO Paul A. Wagner filed a Form 4 detailing the exercise of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Antony A. Riley, CFO of Forte Biosciences, reports the vesting and disposal of restricted stock units.

Paul A. Wagner, CEO of Forte Biosciences, reports the acquisition and disposal of common stock and restricted stock units on April 1, 2025.